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Despite excellent survival of marrow transplantation (BMT) in
acquired severe aplastic anemia (SAA) using sibling donors, graft-
versus-host disease (GVHD) continues to remain a major problem
resulting in long-term complications and impaired quality of life.
Between Aug 1989 and Aug 2004, 35 patients at our centre with
acquired SAA underwent BMT from HLA-identical sibling donors
using cyclophosphamide (CY) 50 mg/kg  4 (days 5 to 2) and
anti-CD52 MoAb 0.75–1 mg/kg BW as conditioning. Prior to
1999, rat derived anti-CD52 MoAb (Campath-1G) was used. We
switched to humanised version of anti-CD52 MoAb (Alemtu-
zumab) when it became available in 1999. Median age at BMT was
17 yrs (range 4–46). Prior to BMT, 58% were heavily transfused
(50 transfusions) and 42% had previously failed ATG. Unma-
nipulated bone marrow was used as source of stem cells in all
except one. GVHD prophylaxis was with cyclosporine (CSA) alone
in 21 (60%) patients; 14 received anti-CD52 MoAb in addition to
CSA. Eight patients had graft failure (primary, 4; secondary, 4)
with a cumulative incidence of 23%. Graft failure was non-signif-
icantly higher in those receiving CSA and anti-CD52 MoAb as
GVHD prophylaxis. No cases of graft failure are seen in 10 pa-
tients treated after 1999. The cumulative incidence of acute grade
II-IV GVHD and chronic GVHD was 13% and 4%, respectively.
None developed extensive chronic GVHD. Of the 19 recipients
positive for cytomegalovirus (CMV), reactivation was seen in 5
(26%) with in 100 days. No cases of late CMV reactivation were
observed. Six patients died of complications related to BMT at a
median of 248 days (range 47–414). With a median follow-up of 59
months, the 5-year survival was 83% (95% C.I. 68–96). There was
a non-signiﬁcant trend towards improved survival in patients trans-
planted after 1995 (94% vs. 74%). Of the 29 survivors, serial
chimerism studies were available on 20 and showed: 100% donor
cells, 15; stable mixed chimerism with 85% donor cells, 3; and
autologous recovery, 2. All survivors are transfusion-independent
and have performance status of 100% except one who developed
avascular necrosis. We conclude that the conditioning regimen
containing CY and anti-CD52 MoAb is well tolerated and efﬁca-
cious for acquired SAA using HLA-matched sibling donors. Based
on the encouraging results of our study, further investigations are
in progress evaluating the role of Alemtuzumab in the transplant
protocols for AA using CSA alone as GVHD prophylaxis.
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IN VIVO SPATIAL AND TEMPORAL ANALYSES IN MICE REVEAL REDUN-
DANCY OF LYMPHOID TISSUES IN INDUCING ACUTE GVHD AFTER
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
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Allogeneic hematopoietic cell transplantation is an effective ther-
apy for the treatment of malignant and non-malignant disorders,
and yet graft-versus-host disease (GVHD) remains a major obsta-
cle. Given the dynamic changes in immune cell subsets and tissue
organization, which occur in GVHD, localization and timing of
critical immunological events in vivo may reveal basic pathogenic
mechanisms of GVHD. We transplanted light-emitting luciferase
transgenic allogeneic splenocytes, and non-invasively monitored
their tissue distribution in living mice with major histocompatibil-
ity differences. Bioluminescence images were used to guide tissue
selection for high-resolution analyses of cell subsets and tissue
distribution. We demonstrated the sequential inﬁltration of lymph
nodes, Peyers patches and spleen by donor derived CD4 T cells
initially, followed by CD8 T cells, and an evolution of homing
receptors that correlated with patterns of cell distribution. These
data underline the important role of secondary lymphoid organs as
sites for GVHD initiation. To determine whether there are in-
structive priming sites for speciﬁc cell migration to GVHD target
organs such as gut, liver and skin we selectively interfered with the
migration of donor T cells to lymphoid organs by administration
of blocking antibodies to L-selectin and MAdCAM-1. Treated
allogeneic recipients interfered with entry of allogeneic splenocytes
into some secondary lymphoid tissues yet still developed GVHD.
Similarly, allogeneic Peyer’s patch deﬁcient recipients manifested
intestinal disease and succumbed to GVHD. These animals were
generated by treatment with lymphotoxin-alpha-IgG fusion pro-
tein during embryonic development. In vivo imaging and detailed
cellular analysis showed that remaining lymphoid tissues compen-
sated for the lack of others. Of importance, T cells that lacked
homing molecules for secondary lymphoid organs had alloreactive
properties in vitro, yet did not cause GVHD in vivo. Transplan-
tation of T cells with deﬁned homing properties therefore appears
to be a promising alternative in conferring protective immunity
early after HCT without the risk of GVHD.
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Introduction: Allogeneic non-myeloablative stem cell transplan-
tation has been shown to reduce systemic toxicity and make pos-
sible the procedure in an ambulatory setting. Objective: To de-
scribe the characteristics of patients selected for an ambulatory
stem cell transplant based on a non-myeloablative chemotherapeu-
tic scheme. Material and Methods: Forty one patients were in-
cluded (26 males and 15 females) with the following diagnoses:
CML (12), CLL (2), ALL (5), AML (10), NHL (3), HL (1), MDS
(3), AA (2), MM (1) and renal cell adenocarcinoma (1). Ages ranged
between 8 and 61 years, with a mean of 36 years. Karnofsky scores
in all patients were superior to 80. All patients tolerated oral
feeding. Hemoglobin values ranged between 6.8 and 15.8 g/dl with
a mean of 12 g/dl. Platelet counts ranged between 14.4  109/L
and 1,200  109/L with a mean of 207.8  109/L. Serum creati-
nine ranged between 0.54 and 2 mg/dL with a mean of 0.9 mg/dL.
Results: Twenty patients completed the transplant on a fully
ambulatory setting basis. All had a Karnofsky scale value of 100.
Mean values were 13 g/dl (hemoglobin), 218.5  109/L (platelets)
and 0.9 g/dL (serum creatinine). Twenty-one patients began the
transplant procedure on an ambulatory basis, but eventually re-
quired admission because of fever and/or mucositis (inpatient days
ranged from 4 to 24 days). Karnofsky scores in these patients
ranged between 80 and 100. Mean values from these patients were
10.9 g/dl (hemoglobin), 195.7  109/L (platelets) and 0.93 mg/dL
(serum creatinine). Conclusions: Half of the patients admitted to
the study completed successfully their stem cell transplantation
procedure on an ambulatory setting. Factors related to this out-
come were normal hematological values after the transplant and
Karnofsky scores  80. These values could predict with a high
degree of probability whether or not a stem cell transplantation
could be successfully performed in an ambulatory setting.
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The dbMHC www.ncbi.nih.gov/mhc is a public resource for the
storage, display and analysis of MHC related genotype and clinical
data. This resource has been developed at National Center for
Bioinformatics (NCBI) through collaboration with the Interna-
tional Histocompatibility Working Group (IHWG). One module
provides public access to data of the Hematopoietic Cell Trans-
plantation project (HCT) of the IHWG. The HCT section of
dbMHC is intended to serve the unmet need of the research and
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